DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A.
Anouk A M T DonnersKonrad van der ZwetAntoine C G EgbertsKarin FijnvandraatRon MathôtIlmar C KruisMarjon H CnossenRoger SchutgensRolf T UrbanusKathelijn FischerPublished in: BMJ open (2023)
V.4.1 on 28 October 2022 (DosEmi protocol_V4.1; NL81112.041.22).